# A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers

> **NCT04045769** · PHASE1 · COMPLETED · sponsor: **Zydus Therapeutics Inc.** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Saroglitazar magnesium 4mg
- **DRUG:** Placebos
- **DRUG:** Moxifloxacin 400mg
- **DRUG:** Saroglitazar magnesium 20 mg

## Key facts

- **NCT ID:** NCT04045769
- **Lead sponsor:** Zydus Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-19
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-12-02
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045769, "A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04045769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*